Chronic graft-versus-host disease (cGVHD) is a common cause of morbidity and mortality in allogeneic bone marrow transplantation (alloBMT). However, effective strategies for the treatment of cGVHD have not been established. In this study, we examined the therapeutic utility of modified dendritic cells (DCs) with a greater capacity to regulate immune responses than previously known tolerogenic DCs, regulatory DCs (DC reg ), in the major histocompatibility complex (MHC)-compatible and multiple minor histocompatibility antigen (miHAg)-incompatible model of cGVHD in alloBMT. Treatment of the recipient mice following alloBMT with the recipient-type DC reg lead to greater suppression of the incidence and severity of cutaneous cGVHD than rapamycin (RAPA), whereas treatment with the recipient-type mature 
histocompatibility antigen (miHAg)-incompatible model of cGVHD in alloBMT. Treatment of the recipient mice following alloBMT with the recipient-type DC reg lead to greater suppression of the incidence and severity of cutaneous cGVHD than rapamycin (RAPA), whereas treatment with the recipient-type mature 
Introduction
Allogeneic bone marrow (BM) transplantation (alloBMT) is an effective treatment forleukemia as well as genetic disorders. [1] [2] [3] However, its success is dependent on the prompt identification of a suitable donor and on the avoidance of opportunistic infections and severe graft-versus-host disease (GVHD). [1] [2] [3] GVHD is mainly due to the activation of alloreactive T cells in the donor BM inoculum. Most therapeutic approaches designed to reduce GVHD have focused on the development of immunosuppressive agents and the ex vivo removal of the unfractionated donor T-cell population from the marrow graft. [1] [2] [3] Although these strategies have reportedly reduced GVHD, there has been a reciprocal increase in the rate of graft rejection, more severe immunosuppression, and lethal infections as well as severe side-effects. [1] [2] [3] GVHD can be divided into acute and chronic forms that likely have different requirements for initiation and pathogenesis. [3] [4] [5] Acute GVHD (aGVHD) and chronic GVHD (cGVHD) are traditionally diagnosed primarily by time of onset, with cGVHD occurring after day 100 after post-transplantation. [3] [4] [5] However, cGVHD has distinct clinicopathologic features and is often diagnosed based on these features regardless of time of onset. [3] [4] [5] aGVHD typically presents with inflammaed skin, gastrointestinal disease, and/or hepatic disease, while cGVHD is characterized by cutaneous fibrosis, the involvement of exocrine glands, myositis, and hepatic disease. [3] [4] [5] Previous studies have suggested that donor-derived CD8 + T cells and residual host antigen (Ag)-presenting cells (APCs) are required for aGVHD, whereas either donor or host APCs play a crucial role in cGVHD mediated by donor-derived CD4 + T cells in murine alloBMT. 4, 5 Relative to aGVHD, much less is understood about an effective therapy for cGVHD due to the limited number of murine models that resemble human cGVHD.
Dendritic cells (DCs), the most potent APCs, are defined by their dendritic morphology, and consist of heterogeneous subsets with a myeloid-or lymphoid-lineage as well as maturity in both lymphoid and peripheral tissues. 6 Immature DCs (iDCs) sense the presence of invading pathogens via various pattern-recognition receptors (PRRs) and process the pathogens intracellularly in inflammed tissues, developing into mature DCs (mDCs) with the upregulation of MHC and costimulatory molecules in inflammatory microenvironments. 6 Subsequently, mDCs home into secondary lymphoid tissues where they present the processed Ags to naïve T cells to generate effector T cells. 6 Thereby, DCs play a crucial role in
For personal use only. on March 31, 2017. by guest www.bloodjournal.org From -4 -the link between innate and adaptive immunity. 6 The induction of tolerance is critical for the maintenance of immune homeostasis. 7, 8 In the thymus, central tolerance is a well-established mechanism that involves clonal deletion of self-reactive T cells. 7, 8 In the periphery, the mechanisms involved include clonal deletion and anergy as well as active suppression by regulatory T (T R depending on environmental conditions. 8, 9 Accumulating indirect evidence suggests that iDCs are involved in the induction of peripheral tolerance under steady state conditions in vivo. 7, 8, 10 On the other hand, the modification of iDCs with certain immunosuppressive molecules generates tolerogenic DCs, which show the defective expression of MHC and costimulatory molecules and then lead to the reduction of T-cell stimulatory capacity. [11] [12] [13] In addition, these tolerogenic DCs not only produce anergic T cells and 15, 16 In this study, we examined the ability of DC reg to control cutaneous cGVHD in MHC-compatible and multiple minor histocompatibility Ag (miHAg)-incompatible alloBMT. BALB/C mice have been described. 17 All mice were used between 5 and 8 weeks of age and maintained in specific pathogen-free conditions and in accordance with guidelines of the Institutional Animal Care
Materials and methods

Mice
Committee of the RIKEN Institute.
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Preparation of DCs
The DCs were prepared as described previously 15, 16 with some modifications. Briefly, mDCs were prepared by culturing BM cells obtained from BALB/C mice with murine granulocyte-macrophage colony-stimulating factor (GM-CSF, 20 ng/ml; Wako Pure Chemical Industries, Osaka, Japan) for 8 days followed by stimulation with lipopolysaccharide (LPS, 1 μg/ml; Sigma-Aldrich, St. Louis, MO) for 24 h.
DC reg were generated from BM cells obtained from BALB/c mice cultured with murine GM-CSF (20 ng/ml), murine IL-10 (20 ng/ml, Wako Pure Chemical Industries) and human transforming growth factor (TGF)-β1 (20 ng/ml, Wako Pure Chemical Industries) for 8 days followed by stimulation with LPS (1 Plasmacytoid DCs (pDCs) were purified from spleen mononuclear cells by AutoMACS with anti-mPDCA-1 microbeads (both from Miltenyi Biotec, Bergisch Gladbach, Germany). In another experiment, DCs (5x10 5 ) were left unstimulated or stimulated with CpG oligodeoxynucleotides (ODN, 0.1μM; Hokkaido System science, Sapporo, Japan) for 24 h, and the culture supernatants were assayed for IL-12p40, IL-10 and interferon (IFN)-α using ELISA kits (BioSource International, Camarillo, CA).
Flow cytometry
Cells were stained with fluorescein-conjugated mAbs to mouse CD4, CD8α, CD11b, CD11c, CD40, CD45RB, CD54, CD80, CD86, H-2K d , I-A/I-E, 33D1, B220, Gr-1, isotype-matched control mAb (BD Bioscience), Foxp3 (eBioscience, San Diego, CA), CD25, mPDCA-1 (Miltenyi Biotec), CD205 (SeroTec, Raleigh, NC), and KJ1-26 (Caltag Laboratories, Burlingame, CA). For analysis of the intracellular expression of cytokines, cells were stimulated with immobilized anti-CD3 mAb and soluble anti-CD28 mAb (each 10 μg/ml; both from BD Bioscience) for 5 h in the presence of Golgi Block (BD Biosciences).
Intracellular staining was performed using a Cytofix/Cytoperm kit, and mAbs to IL-2, IL-4, IL-10 and T cells (10 6 ) and DC reg (10 5 incorporation was measured on day 3 for the last 18h.
Ag-presentation assay
Models for cGVHD and the evaluation
The induction and the evaluation of cGVHD were performed according to previous reports 4, 5 with some modifications. In brief, recipient BALB/C mice (ten per group) received a single dose (800 cGy) of lethal total body irradiation (TBI). Three hours following the TBI, all recipients received T-cell-depleted BM cells Recipients were monitored once every day from the day of transplantation to the indicated days after transplantation to determine the incidence and severity of cutaneous cGVHD as well as mobility, diarrhea, and weight loss. The following scoring system for cutaneous cGVHD was used: healthy appearance equals 0; skin lesions with alopecia less than 1 cm 2 in area, 1; skin lesions with alopecia 1 to 2 cm 2 in area, 2; skin 
Statistical analysis.
Data are expressed as mean values ± standard deviation (SD). All analyses for statistically significant differences were performed with the Student paired t test or the Log-Rank test. *P values <0.01 were considered significant. Figure 3A and 3B). In contrast, treatment with the recipient-type DC reg suppressed the incidence and severity of cutaneous cGVHD as compared with the untreated recipient mice (P<0.01, Figure 3A and 3B), and these protected mice had little or no signs of cutaneous cGVHD over 120 days.
We also examined serum levels of TNF-α, IL-12p40, IFN-γ, and IL-4 in the transplanted recipient mice (Figure 4) . Treatment with the recipient-type mDCs markedly enhanced serum production of TNF-α, IL-12p40, and IFN-γ, whereas serum production of IL-4 was inhibited possibly due to the IL-12-mediated
For personal use only. on March 31, 2017. by guest www.bloodjournal.org From -11 -induction of T type-1 helper (T H 1) cells, when compared to levels in the untreated recipient mice. In contrast, treatment with the recipient-type DC reg significantly inhibited serum levels of TNF-α, IL-12p40, IFN-γ and IL-4, whereas RAPA had little or no effect on serum production of these cytokines.
To determine the therapeutic effect of DC reg on cutaneous cGVHD, the transplanted recipient mice received repetitive i.v. injections of the recipient-type DC reg on days 18, 25 and 32 after transplantation, and the incidence and severity of cutaneous cGVHD were monitored ( Figure 3C and 3D) . Treatment with the recipient-type DC reg even after disease onset not only suppressed the severity, but also reduced the incidence, of cutaneous cGVHD. cGVHD has distinct clinicopathologic features and different requirements for initiation and development from aGVHD, and an effective means of treating cGVHD remains to be established. 4, 5 Indeed, the traditional treatment with RAPA failed to suppress the incidence and severity of cutaneous cGVHD, although this treatment was reportedly effective in preventing aGVHD-induced lethality. 23 A series of studies have reported that iDCs had a preventive effect in several murine models of the immunopathogenic diseases. 11 However, the clinical application of iDCs may not be suitable for the treatment of immunopathogenic diseases, because they likely mature under inflammatory conditions. 8 Indeed, our preliminary experiments showed that treatment with recipient-type iDCs as well as semi-mDCs following allogeneic transplantation did not suppress the incidence or severity of cutaneous cGVHD (data not shown).
Involvement of in vivo-
On the other hand, treatment with recipient-type DC reg significantly protected the allogeneic transplanted mice from cutaneous cGVHD. We also observed that DC reg derived from donor mice or other strains had little or no inhibitory effect (data not shown). Therefore, the immunotherapeutic strategy using recipient-type DC reg might have preventive and therapeutic potential for the treatment of cGVHD. In summary, the findings reported here highlight a novel immunotherapeutic approach using DC reg for the treatment of cGVHD. We have previously reported that the recipient-type DC reg protected mice from death due to aGVHD in murine fully MHC-mismatched alloBMT. 15 In addition, human DC reg exhibited similar a 16 Therefore, the availability of human DC reg may provide an advantageous means of Ag-specific intervention for cGVHD as well as aGVHD in alloBMT.
To test our hypothesis, the development of an immunotherapy with human DC reg is also being conducted in our laboratories. In addition, further insight into the molecular mechanism underlying the DC reg -mediated regulation of T cell-function may lead to a better understanding of the induction of peripheral tolerance. Results of three replicated experiments were pooled.
For
